Join our daily newsletter At The Bell to receive exclusive market insights
- INOVIQ (IIQ) receives an Australian patent for its SubB2M technology, which the company now holds exclusive worldwide rights to the IP for its diagnostic applications
- The company was awarded the Australian Patent number 2017358401 entitled “Subtilase cytotoxin B subunit mutant”, issued to Griffith University and the University of Adelaide
- The patent is due to expire on November 9, 2037
- The granting of the Australian patent is another important step in the company’s path to commercialisation for its SubB2M-based tests and follows other recent key milestones
- IIQ shares are up 6.14 per cent, trading at 60.5 cents
INOVIQ (IIQ) has been granted an Australian patent for its SubB2M technology and now holds exclusive worldwide rights to the SubB2M intellectual property for diagnostic applications.
The company was awarded the Australian Patent number 2017358401 entitled “Subtilase cytotoxin B subunit mutant”, issued by IP Australia to Griffith University and the University of Adelaide.
The patent is due to expire on November 9, 2037 and claims modified SubB proteins, capable of binding N-glycolylneuraminic acid (Neu5Gc) and variants and fragments thereof, such as SubB2M.
“This patent enforces intellectual property protection in Australia for INOVIQ’s SubB2M-based diagnostics pipeline for monitoring of breast and ovarian cancers,” CEO Dr Leearne Hinch said.
Dr Hinch said this is also the first patent granted for the SubB2M technology and marks a key step in INOVIQ’s path to commercialising its SubB2M-based tests.
The patent also follows other key milestones including the signing of a master services agreement with ResearchDX and a master manufacturing agreement with MP Biomedicals.
The SubB2M diagnostics pipeline is now undergoing further feasibility testing, development, and validation at US-based contract diagnostic organisation, ResearchDx.
IIQ shares were up 6.14 per cent, trading at 60.5 cents at 2:06 pm AEST.
